Shay Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Shay Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,000	Closed	-$1.98M	–	554
2025 Q3	$1.98M	Buy	+15,000	New	+$1.8M	0.17%	118

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Shay Capital's JAZZ Position: Q4 2025 in Review

Shay Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 15,000 shares — an estimated $1.98M sold.

Shay Capital first reported a position in JAZZ in Q3 2025 and held it in 1 quarter. The position peaked at $1.98M in Q3 2025. 576 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

Shay Capital reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Shay Capital sold 15,000 Jazz Pharmaceuticals shares in Q4 2025, an estimated $1.98M.
Shay Capital first reported a position in Jazz Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Shay Capital's Jazz Pharmaceuticals position peaked at $1.98M in Q3 2025.
576 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Shay Capital's 13F filing for Q4 2025, filed 17 Feb 2026.